Senior/Principal Clinical Database Manager

👩‍🍳 How we use AI at Tech in Asia, thoughtfully and responsibly.🧔‍♂️ A friendly human may check it before it goes live. More news hereMirxes Holding Company has detailed its global offering and listing on the Main Board of the Hong Kong Stock Exchange.The offering includes 46,620,000 shares, which consist of 4,662,000 shares for the Hong Kong public offer and 41,958,000 shares for the international offer, subject to reallocation.The public offering in Hong Kong runs from May 15 to May 20, 2025.Shares will start trading on May 23, 2025, under stock code 2629.At HK$23.30 (US$2.98) per share, Mirxes expects to raise HK$880.5 million (US$112.7 million).These funds will be allocated for research and development of its core product GASTROClear, development of other pipeline products, strengthening operational capabilities, and general corporate purposes.🔗 Source: Mirxes🧠 Food for thought1️⃣ Biotech IPOs face a more selective environment in 2025Mirxes’ IPO comes during a period of increased investor scrutiny for biotech companies, reflecting a shift from the exuberance of previous years.The global biotech sector experienced a record fundraising year in 2018 with $8.2 billion raised across numerous IPOs, including Moderna’s landmark $604 million offering 1.Today’s market shows greater selectivity, with investors now prioritizing companies demonstrating proven clinical data and clear paths to market, raising the bar for IPO valuations 2.This transformation mirrors historical patterns in biotech investment cycles, where periods of enthusiasm are followed by more cautious assessment, as seen in the 1991-1994 window when nearly 100 biotech companies went public, though many later struggled to maintain their valuations 3.Mirxes will need to effectively communicate its value proposition in this environment where, according to recent reports, many high-quality private companies are choosing to remain private longer due to favorable private capital access 2.2️⃣ Gastric cancer diagnostics represents a growing market opportunityMirxes’ focus on GASTROClear™ for gastric cancer detection positions it in a diagnostics market projected to expand significantly in coming years.The global gastric cancer diagnostic procedure market is expected to grow from $1.30 billion in 2022 to $1.91 billion by 2028, representing a compound annual growth rate of 6.5% 4.This growth is driven by rising prevalence of gastrointestinal diseases and increasing cases of Helicobacter pylori infections, highlighting the clinical need that Mirxes’ technology addresses 4.MiRXES has developed GASTROClear as a liquid biopsy test that assesses 12 microRNA biomarkers for early gastric cancer detection, leveraging advanced molecular diagnostic techniques that align with broader industry trends toward precision medicine 5.With approximately 26,500 new gastric cancer cases estimated in the U.S. alone for 2023, the company is targeting a substantial clinical need that could support its commercial aspirations if it can demonstrate superior diagnostic capabilities 4.3️⃣ Allocation of IPO proceeds reveals strategic priorities in competitive diagnostics landscapeMirxes’ planned use of its IPO proceeds highlights its focus on both product development and building integrated capabilities across the diagnostic value chain.The company is allocating 51% of proceeds to its core product GASTROClear™, with 24% for pipeline development and 15% for strengthening “end-to-end” capabilities—a distribution that reflects lessons from successful diagnostic companies.This approach mirrors the broader industry trend of diagnostic companies needing to demonstrate comprehensive solutions rather than standalone tests, as 75% of life sciences executives surveyed express optimism about sector growth in 2025 despite market challenges 6.The allocation toward integrated capabilities aligns with observations that successful biotech companies increasingly require strategic partnerships and consolidated services spanning scientific, clinical, and commercial expertise 7.With 36% of life sciences executives prioritizing customer engagement and experience improvements, Mirxes’ investment in end-to-end capabilities suggests awareness of the evolving requirements for market success beyond just technical validation 6

-- Brings over two decades' experience leading business development and crafting go-to-market solutions for clinical research organizations --BETHESDA, Md., April 29, 2025 /PRNewswire/ -- Precision for Medicine, a global leader in biomarker-driven clinical research and development, today announced the appointment of Matt Grow as Chief Commercial Officer. In this role, Mr. Grow will focus on implementing a go-to-market strategy that positions Precision for Medicine as the premier partner to help life science companies accelerate clinical research and development